StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
ABLD.PA$3.24+1.25%
Fair $3.24+0.0%

ABLD.PA

ABL Diagnostics Société anonyme

Healthcare / Health Information ServicesParis

$3.24

+0.04 (+1.25%)

Fairly Valued+0.0%Fair Value $3.24Fund rank 29/100 · Data gapFallback financials|
SA 38/D
F-Score: 7/9

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 26% · confianza 25%

FCF escenarios

weak_data · normalized FCF $-800415.00 · quality 60.3/100

Data gap 29/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 35/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

38/100

D

Piotroski

7/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 0unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Insufficient audited annual history (<3 SEC-backed years); composite fair value and forward targets are disabled until manually verified.
Thesis & Journal · ABLD.PALocal privado en este navegador · ABL Diagnostics Société anonyme
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$52M

P/E

54.0x

↑

EV/EBITDA

52.6x

↑

ROE

12.9%

↑

Gross Margin

95.3%

↑

Debt/Equity

0.29

↑
52-Week Range$3
$2$6

TradingView lightweight chart

ABLD.PA price, volumen y niveles de valoración

Último $3.240Periodo +220.0%
Fair value: $3.240

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2022–2025 · 3 años de histórico normalizado

Revenue CAGR

-7.4%

FCF CAGR

—

FCF margin

10.3%

FCF / Net income

0.72x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $7.0M · net income $986695.0 · FCF $714760.0

2022-FY → 2025-FY

Gross margin

95.3%+0.2% pts

Operating margin

4.2%+3.5% pts

Net margin

14.2%+1.6% pts

FCF margin

10.3%— pts
MetricTTM
2025
2024
2023
2022
Income Statement
Revenue$7.0M$7.0M$5.3M$5.6M$8.7M
Net Income$986695.00$986695.00$285170.00$54363.00$1.1M
EBITDA$1.0M$1.0M$334058.00$45425.00$651064.00
EPS——0.020.000.07
Gross Margin95.3%95.3%90.7%86.9%95.1%
Operating Margin4.2%4.2%-9.1%-11.7%0.7%
Net Margin14.2%14.2%5.3%1.0%12.6%
Balance Sheet
Debt/Equity0.290.290.340.510.39
Current Ratio3.083.08———
Cash Flow
Free Cash Flow$714760.00$714760.00$-2.3M——
Returns
ROE12.9%12.9%3.8%0.8%16.4%
Valuation
P/E54.0054.00138.862874.93210.62
EV/EBITDA52.5652.56124.753468.33360.21
P/B6.826.825.2923.1034.48
Growth & Yield
Revenue Growth30.4%30.4%-5.0%-35.8%—
EPS Growth——425.1%-95.1%—
Dividend Yield3.4%3.4%———

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%
Reverse DCF requires positive EPS; loss-making or zero-EPS companies cannot produce a clean EPS hurdle.

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total -36.6%

Total return

-36.6%

Start / end P/E

n/dx → n/dx

EPS bridge

0.02 → n/d

Residual

-40.0%

EPS growthn/d
Multiple reratingn/d
Dividend+3.4%
Residual / FX / buybacks / cross-term-40.0%

EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.